Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Trade Desks prolonged slide to multiyear lows is being tied to worries about softer ad spending and slowing growth, alongside competition from Amazon and other automated advertising platforms; claims about Apple/Safari blocking its ads remain disputed. Traders are sharply divided, with many criticizing CEO Jeff Green and his proposed compensation while bullish voices point to the companys cash generation and see the selloff as potentially overdone.

Attention centers on the judges pause in the marijuana rescheduling hearing while the DEA responds to a GAO report on gaps in federal scheduling procedures, clouding the timing of the anticipated Schedule III recommendation. Traders disagree over whether it is a limited procedural delay or a sign of further setbacks; some are buying the dip while others express frustration with the uncertainty.

Microns upcoming fiscal Q4 earnings and forward outlook are the dominant focus, with traders watching whether tight AI-driven DRAM, NAND and HBM supply can sustain pricing and growth. Many expect strong results, while others warn that optimism may already be priced in and debate the risk of a post-earnings selloff or a shorter-than-expected memory cycle.

Ryan Cohens reported share purchases are driving attention, with bullish traders treating the insider buying as a vote of confidence and potential support for a squeeze. Others argue the purchases alone are not enough to sustain a move, pointing to the lack of a new business catalyst and uncertainty around the warrants.

Iovance shares surged after the company raised its full-year revenue outlook on stronger demand for Amtagvi and Proleukin, reinforcing confidence in its commercial launch. Traders largely welcomed the update as validation and speculated about short covering, while others warned of overbought conditions or potential dilution; many also pointed to upcoming lung-cancer data as a catalyst.

FHFA changes allowing Fannie Mae and Freddie Mac to use VantageScore alongside FICO are fueling concern that competition could erode FICOs long-standing mortgage-scoring advantage, prompting a sharp selloff. Traders debate whether the threat to its moat justifies the decline or whether the market is overreacting, with some buying the dip and others expecting further pressure.

A pause in the DEA cannabis-rescheduling hearing is driving discussion, with traders focused on a judges request for the agency to respond on whether the record should be reopened to include a GAO report. Some view the resulting delay as limited and remain optimistic about Schedule III rescheduling, while others are frustrated by the uncertain timeline.

AstraZenecas strategic investment and clinical-trial collaboration around ivonescimab are driving attention, with traders viewing the deal as major-pharma validation and relief from financing concerns. Others point to dilution and caution that the investment is not a buyout; the FDA decision on ivonescimab remains a separate, uncertain catalyst.

Evernorths transition from the Armada SPAC to trading as XRPN is driving attention, with the companys planned XRP treasury strategy seen by bullish traders as a way to gain exposure to XRP through a Nasdaq-listed stock. Enthusiasm around the ticker change and warrants is balanced by questions about valuation, thin trading activity, and the risks of the SPAC transition.

DraftKings is under pressure amid concerns that Kalshi and Polymarket are competing for sportsbook customers, alongside uncertainty over how prediction markets will be regulated. Bears worry that competition and investment spending will weigh on margins, while bulls point to growth in DraftKings own prediction-market product and sportsbook business as reasons the company could benefit under either regulatory outcome.